270 related articles for article (PubMed ID: 32532461)
1. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection.
Callejas Rubio JL; Luna Del Castillo JD; de la Hera Fernández J; Guirao Arrabal E; Colmenero Ruiz M; Ortego Centeno N
Med Clin (Barc); 2020 Aug; 155(4):159-161. PubMed ID: 32532461
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection.
Callejas Rubio JL; Luna Del Castillo JD; de la Hera Fernández J; Guirao Arrabal E; Colmenero Ruiz M; Ortego Centeno N
Med Clin (Engl Ed); 2020 Aug; 155(4):159-161. PubMed ID: 32835105
[TBL] [Abstract][Full Text] [Related]
3. [Evolution and treatment of storm cytoquine syndrome associated to SARS-CoV-2 infection among octogenarians].
Callejas Rubio JL; Aomar Millán I; Moreno Higueras M; Muñoz Medina L; López López M; Ceballos Torres Á
Rev Esp Geriatr Gerontol; 2020; 55(5):286-288. PubMed ID: 32564984
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
[TBL] [Abstract][Full Text] [Related]
5. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
Ramiro S; Mostard RLM; Magro-Checa C; van Dongen CMP; Dormans T; Buijs J; Gronenschild M; de Kruif MD; van Haren EHJ; van Kraaij T; Leers MPG; Peeters R; Wong DR; Landewé RBM
Ann Rheum Dis; 2020 Sep; 79(9):1143-1151. PubMed ID: 32719045
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
[TBL] [Abstract][Full Text] [Related]
7. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
[TBL] [Abstract][Full Text] [Related]
8. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
[TBL] [Abstract][Full Text] [Related]
9. Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.
Gautier-Vargas G; Baldacini C; Benotmane I; Keller N; Perrin P; Moulin B; Caillard S
Kidney Int; 2020 Aug; 98(2):508-509. PubMed ID: 32505467
[No Abstract] [Full Text] [Related]
10. Tocilizumab for severe COVID-19: a systematic review and meta-analysis.
Lan SH; Lai CC; Huang HT; Chang SP; Lu LC; Hsueh PR
Int J Antimicrob Agents; 2020 Sep; 56(3):106103. PubMed ID: 32712333
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C;
J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab administration in a refractory case of COVID-19.
Dastan F; Nadji SA; Saffaei A; Tabarsi P
Int J Antimicrob Agents; 2020 Aug; 56(2):106043. PubMed ID: 32502524
[No Abstract] [Full Text] [Related]
14. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
[No Abstract] [Full Text] [Related]
15. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience.
Zain Mushtaq M; Bin Zafar Mahmood S; Jamil B; Aziz A; Ali SA
Int Immunopharmacol; 2020 Nov; 88():106926. PubMed ID: 32889236
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
Ranger A; Haji R; Kaczmarski R; Danga A
Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422
[No Abstract] [Full Text] [Related]
17. Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan.
Tu WJ; Cao J; Yu L; Hu X; Liu Q
Intensive Care Med; 2020 Jun; 46(6):1117-1120. PubMed ID: 32253448
[No Abstract] [Full Text] [Related]
18. Early tocilizumab treatment could improve survival among COVID-19 patients.
Campins L; Boixeda R; Perez-Cordon L; Aranega R; Lopera C; Force L
Clin Exp Rheumatol; 2020; 38(3):578. PubMed ID: 32456769
[No Abstract] [Full Text] [Related]
19. COVID-19 and Hypercoagulability.
Sholzberg M
Clin Adv Hematol Oncol; 2020 Jul; 18(7):386-389. PubMed ID: 32903249
[No Abstract] [Full Text] [Related]
20. Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19.
Faguer S; Del Bello A; Abravanel F; Nicolau-Travers ML; Kamar N
Ann Intern Med; 2020 Sep; 173(6):501-503. PubMed ID: 32432518
[No Abstract] [Full Text] [Related]
[Next] [New Search]